TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
MedPage Today published a weekly collection of comments from clinicians and health leaders on developments ranging from FDA action over unapproved herpes treatments to measles response and hospital infection prevention. The roundup also covers studies involving vaping exposure, a rare fungal infection, treatment-resistant depression and retinal disease; it is a compilation of reactions, not a single new policy or clinical finding.
MedPage Today published a weekly roundup on October 11 featuring comments from physicians, a nursing leader and other health professionals about current medical news, including FDA warnings over unapproved herpes treatments and the U.S. measles outbreak. The article collects reactions to separate developments; it does not announce a single new medical policy or study.
The quote roundup, titled “The Public Should Not be Subject to These Quack Medicines”: What We Heard This Week, opens with Jeffrey Klausner, a physician with Herpes Cure Advocacy, reacting to news that the FDA warned Amazon for selling unapproved herpes treatments. Klausner said the public should not be exposed to what he called “quack medicines.” The source does not provide details of the FDA warning or the products involved.
Other comments address the federal response to measles, the role of nurses in politics and hospital efforts to prevent catheter-associated urinary tract infections. Former NIAID Director Jeanne Marrazzo criticized the government’s response to the U.S. measles outbreak as “extremely underwhelming and frankly shameful.” American Nurses Association President Jennifer Mensik Kennedy pointed to 18 nurses running for Congress, arguing that more nurses should hold public office.
The remaining remarks refer to research and clinical issues: vaping exposure among children with asthma; a rise in a rare, potentially deadly fungal infection; radiosurgical capsulotomy studied for treatment-resistant depression and suicidal thoughts; and optogenetic therapy being investigated for advanced retinitis pigmentosa. The roundup supplies brief descriptions and reactions, rather than full study results or detailed evidence.
Health Issues Behind the Quotes
The roundup puts public health, patient safety and access to care in view through the people working in those fields. Its comments underscore concerns about unapproved products being sold to consumers, the response to an outbreak, and practical measures hospitals may use to reduce infection risk. Those views are attributable opinions, not independent findings established by the roundup.
It also points readers toward areas where evidence and clinical options may still be developing. The comments on depression and retinal disease refer to research that could interest patients and clinicians, but the article does not establish that either approach is proven, widely available or suitable for routine care. Readers need the underlying studies and their limitations to judge what the findings mean.
As an affiliate, we earn on qualifying purchases.
A Weekly Roundup, Not One Study
MedPage Today described the piece as a collection of quotations heard by its reporters during the week. It was published as a two-minute-read roundup on October 11, 2026. Each quotation is tied to a separate news item or topic, so the comments should not be read as one coordinated statement or as a report of a single event.
The topics range from regulatory action and outbreak response to infection prevention and experimental therapies. The source gives speakers’ names and professional affiliations, along with a short explanation of what they were discussing. It does not include links to the underlying FDA notice, outbreak data, hospital findings or full research papers in the supplied material.
“The public should not be subject to these quack medicines.”
— Jeffrey Klausner, MD, MPH, of Herpes Cure Advocacy
As an affiliate, we earn on qualifying purchases.
Details Behind the Comments
The roundup does not provide enough detail to independently evaluate the FDA warning, measles response or cited studies. It does not state which herpes products were involved, what the agency told Amazon, or what steps followed. It also offers no outbreak figures or specific measures by which the federal response could be assessed.
For the research topics, the article supplies no study sizes, methods, comparison groups or full outcome data. A speaker described results from a small study of radiosurgical capsulotomy as potentially life-saving, but that is a qualified comment, not proof of effectiveness. The material also does not identify the fungal infection’s case count or explain the reported increase. Further reporting and the original studies would be needed to clarify these points.
hospital infection prevention supplies
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Follow-Up on Warnings and Research
The next steps depend on the separate developments summarized. Readers seeking details on the Amazon warning would need the FDA’s notice or subsequent agency and company statements. Further public health updates and official data would help show how the measles response is changing and what actions are being taken.
For the clinical topics, the key milestones are fuller publication and independent evaluation of the cited research, along with any follow-up studies or guidance from relevant health authorities. No specific next announcement or deadline is given in MedPage Today’s roundup.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did MedPage Today publish on October 11, 2026?
It published a weekly collection of health-related quotes from reporters’ conversations and coverage. The comments address several separate news developments rather than one event.
What prompted Jeffrey Klausner’s comment about herpes treatments?
Klausner was responding to news that the FDA warned Amazon for selling unapproved herpes treatments. The supplied roundup does not identify the products or give the warning’s full details.
Did the roundup report a new measles policy?
No. It quoted former NIAID Director Jeanne Marrazzo criticizing the federal government’s response to the U.S. measles outbreak; it did not announce a new policy or provide outbreak figures.
Did the article establish that the experimental treatments work?
No. Its remarks on radiosurgical capsulotomy and optogenetic therapy refer to research topics, but the roundup does not provide enough study detail to establish effectiveness, safety or routine availability.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
